Imgenex to develop Mabs (monoclonal antibodys) for osteoporosis assessment:
This article was originally published in Clinica
Executive Summary
Imgenex of San Diego, California, has been awarded a phase I small business innovation and research (SBIR) grant worth $100,000 to develop monoclonal antibodies that recognise signalling molecules involved in the aetiology of osteoporosis. The company says the antibodies will allow more reliable prediction and earlier detection of osteoporosis and may also have therapeutic applications.